Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)

4.04
Delayed Data
As of Jan 22
 +0.23 / +6.04%
Today’s Change
2.85
Today|||52-Week Range
9.40
+17.10%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$29.8M

Company Description

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company, which engages in the development of innovative pharmaceutical products to public health challenges. It focuses on delivering an efficacious, and safe long-term treatment for posttraumatic stress disorder. It also includes TNX-102 SL, TNX-601, TNX-801, TNX-301, and TNX-701. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

Contact Information

Tonix Pharmaceuticals Holding Corp.
509 Madison Avenue
New York New York 10022
P:(212) 980-9155
Investor Relations:
(212) 980-9159

Employees

Shareholders

Mutual fund holders3.26%
Other institutional25.94%
Individual stakeholders2.33%

Top Executives

Seth LedermanChairman, President & Chief Executive Officer
Jessica Edgar MorrisChief Operating Officer
Bradley SaengerChief Financial Officer & Treasurer
Gregory M. SullivanSecretary & Chief Medical Officer
Ronald R. NotvestSenior VP-Commercial Planning & Development